BACKGROUND: Abnormal oscillatory neural activity in the beta-frequency band (13-35 Hz) is thought to play a role in Parkinson's disease (PD); however, increasing evidence points to alterations in high-frequency ranges (>100 Hz) also having pathophysiological relevance. OBJECTIVES: Studies have found that power in subthalamic nucleus (STN) high-frequency oscillations is increased with dopaminergic medication and during voluntary movements, implicating these brain rhythms in normal basal ganglia function. The objective of this study was to investigate whether similar signaling occurs in the internal globus pallidus (GPi), a nucleus increasingly used as a target for deep brain stimulation (DBS) for PD. METHODS: Spontaneous and movement-related GPi field potentials were recorded from DBS leads in 5 externalized PD patients on and off dopaminergic medication, as well as from 3 rhesus monkeys before and after the induction of parkinsonism with the neurotoxin 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine. RESULTS: In the parkinsonian condition, we identified a prominent oscillatory peak centered at 200-300 Hz that increased during movement. In patients the magnitude of high-frequency oscillation modulation was negatively correlated with bradykinesia. In monkeys, high-frequency oscillations were mostly absent in the naive condition but emerged after the neurotoxin 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine. In patients, spontaneous high-frequency oscillations were significantly attenuated on-medication. CONCLUSIONS: Our findings provide evidence in support of the hypothesis that exaggerated, movement-modulated high-frequency oscillations in the GPi are pathophysiological features of PD. These findings suggest that the functional role(s) of high-frequency oscillations may differ between the STN and GPi and motivate additional investigations into their relationship to motor control in normal and diseased states.
BACKGROUND: Abnormal oscillatory neural activity in the beta-frequency band (13-35 Hz) is thought to play a role in Parkinson's disease (PD); however, increasing evidence points to alterations in high-frequency ranges (>100 Hz) also having pathophysiological relevance. OBJECTIVES: Studies have found that power in subthalamic nucleus (STN) high-frequency oscillations is increased with dopaminergic medication and during voluntary movements, implicating these brain rhythms in normal basal ganglia function. The objective of this study was to investigate whether similar signaling occurs in the internal globus pallidus (GPi), a nucleus increasingly used as a target for deep brain stimulation (DBS) for PD. METHODS: Spontaneous and movement-related GPi field potentials were recorded from DBS leads in 5 externalized PD patients on and off dopaminergic medication, as well as from 3 rhesus monkeys before and after the induction of parkinsonism with the neurotoxin 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine. RESULTS: In the parkinsonian condition, we identified a prominent oscillatory peak centered at 200-300 Hz that increased during movement. In patients the magnitude of high-frequency oscillation modulation was negatively correlated with bradykinesia. In monkeys, high-frequency oscillations were mostly absent in the naive condition but emerged after the neurotoxin 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine. In patients, spontaneous high-frequency oscillations were significantly attenuated on-medication. CONCLUSIONS: Our findings provide evidence in support of the hypothesis that exaggerated, movement-modulated high-frequency oscillations in the GPi are pathophysiological features of PD. These findings suggest that the functional role(s) of high-frequency oscillations may differ between the STN and GPi and motivate additional investigations into their relationship to motor control in normal and diseased states.
Authors: Takao Hashimoto; Christopher M Elder; Michael S Okun; Susan K Patrick; Jerrold L Vitek Journal: J Neurosci Date: 2003-03-01 Impact factor: 6.167
Authors: Paul Silberstein; Andrea A Kühn; Andreas Kupsch; Thomas Trottenberg; Joachim K Krauss; Johannes C Wöhrle; Paolo Mazzone; Angelo Insola; Vincenzo Di Lazzaro; Antonio Oliviero; Tipu Aziz; Peter Brown Journal: Brain Date: 2003-08-22 Impact factor: 13.501
Authors: Anders Christian Meidahl; Gerd Tinkhauser; Damian Marc Herz; Hayriye Cagnan; Jean Debarros; Peter Brown Journal: Mov Disord Date: 2017-06 Impact factor: 10.338
Authors: Bernadette C M van Wijk; Martijn Beudel; Ashwani Jha; Ashwini Oswal; Tom Foltynie; Marwan I Hariz; Patricia Limousin; Ludvic Zrinzo; Tipu Z Aziz; Alexander L Green; Peter Brown; Vladimir Litvak Journal: Clin Neurophysiol Date: 2016-02-01 Impact factor: 3.708
Authors: Mark D Grier; Essa Yacoub; Gregor Adriany; Russell L Lagore; Noam Harel; Ru-Yuan Zhang; Christophe Lenglet; Kâmil Uğurbil; Jan Zimmermann; Sarah R Heilbronner Journal: Neuroimage Date: 2022-04-13 Impact factor: 7.400
Authors: Ajay K Verma; Sergio Francisco Acosta Lenis; Joshua E Aman; David Escobar Sanabria; Jing Wang; Amy Pearson; Meghan Hill; Remi Patriat; Lauren E Schrock; Scott E Cooper; Michael C Park; Noam Harel; Michael J Howell; Colum D MacKinnon; Jerrold L Vitek; Luke A Johnson Journal: NPJ Parkinsons Dis Date: 2022-09-12